Corcept Therapeutics (CORT) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed Corcept Therapeutics (CORT) over the past year, gaining 68.4% versus a gain of 32.4%. Over five years, CORT leads with a +496.8% price change compared with +64.3% for JAZZ. Jazz Pharmaceuticals is the larger company by market cap ($15.01 billion vs $12.93 billion), about 1.2 times the size, while Corcept Therapeutics is growing revenue faster (+12.8% vs +4.9%).
On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.9x vs 27.2x for Corcept Therapeutics). Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -8.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CORT | JAZZ |
|---|---|---|
| Share price | $119.60 | $231.19 |
| Market cap | $12.93B | $15.01B |
| 1-day change | +0.03% | -0.09% |
| YTD return | +243.68% | +35.99% |
| 1-year return | +32.42% | +68.36% |
| 5-year return | +496.81% | +64.31% |
| P/E ratio (TTM) | 265.78 | 15.86 |
| Forward P/E | 27.17 | 8.93 |
| EPS (TTM) | $0.45 | $14.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $761.41M | $4.27B |
| Revenue growth (YoY) | +12.79% | +4.88% |
| Net income (latest FY) | $99.65M | $-356.15M |
| Gross margin | 98.30% | — |
| Operating margin | 5.88% | -10.08% |
| Net margin | 13.09% | -8.35% |
| 52-week high | $126.38 | $266.38 |
| 52-week low | $28.66 | $128.80 |
| Distance from 52-week high | -5.36% | -13.21% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +17.89% | +27.38% |
| Average volume | 1.31M | 854.86K |
| Shares outstanding | 108.10M | 64.91M |
| Employees | 730 | 2,890 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed CORT by 35.9 percentage points over the past year.
- Corcept Therapeutics trades at a higher earnings multiple (265.8x vs 15.9x trailing P/E).
- Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -8.3 cents for Jazz Pharmaceuticals.
- Corcept Therapeutics grew revenue faster in its latest fiscal year (+12.79% vs +4.88%).
- The two companies sit in different sectors: Corcept Therapeutics in Health Care and Jazz Pharmaceuticals in Healthcare.
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Healthcare · Biotechnology · 2,890 employees
CORT vs JAZZ FAQ
Which is bigger, Corcept Therapeutics or Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) is larger, with a market capitalization of $15.01B compared with $12.93B for Corcept Therapeutics (CORT).
Which stock has performed better over the past year, CORT or JAZZ?
JAZZ returned +68.36% over the past 12 months, compared with +32.42% for CORT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CORT or JAZZ?
JAZZ has the lower trailing P/E at 15.9, versus 265.8 for CORT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Corcept Therapeutics and Jazz Pharmaceuticals in the same industry?
No. Corcept Therapeutics is in the Health Care sector, while Jazz Pharmaceuticals is in Healthcare.